News & Trends

• 142023-12

  Salubris' innovative drugs Allisartan and Enarodustat® were enrolled into 2023 National Reimbursement Drug List(NRDL)

• 102023-10

  New overseas clinical progress of JK07 for the treatment of chronic heart failure (HFrEF)

• 082023-10

  SAL0120 tablets for treatment of IgA nephropathy approved for clinical trial

• 102023-08

  Vena cava filter system (SaExten®) approved by NMPA

• 092023-06

  Enarodustat（恩那罗®） Approved by NMPA for Treatment of Renal Anemia (Abstract) NMPA approved Enarodustat（恩那罗®）

• 052023-02

  The clinical progress of SAL0119 tablets for the treatment of ankylosing spondylitis and rheumatoid arthritis